Since bevacizumab, an anti-VEGF antibody, appears to be more efficient in TRN breast cancer (35), stromal CD74 expression could be examined as a predictive marker of response to bevacizumab-based therapy. This evidence concerns the gene CD74 and breast carcinoma.